Enovis Corporation/$ENOV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Enovis Corporation

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Ticker

$ENOV
Sector

Primary listing

NYSE

Employees

7,367

ENOV Metrics

BasicAdvanced
$1.8B
-
-$14.68
1.81
-

Bulls say / Bears say

Enovis’ second-quarter 2025 net sales rose 7% year-over-year to $564.54 million, surpassing analyst expectations and reflecting steady end markets and strong product momentum. (Reuters)
The company’s Q2 adjusted earnings per share of $0.79 beat consensus by $0.07, showing higher operational efficiency. (Reuters)
Enovis raised its full-year 2025 revenue outlook to $2.245–$2.275 billion and increased adjusted EPS guidance to $3.05–$3.20, signaling management’s confidence in sustained growth. (Reuters)
Enovis cut its annual adjusted profit outlook to $2.95–$3.10 per share from $3.10–$3.25, indicating margin pressure from tariffs and integration costs. (Reuters)
Shares are underperforming due to tariff concerns, according to Evercore ISI, reflecting worry about the company’s $40 million annual tariff exposure. (Reuters)
Enovis shares dropped 4% after reiterating its Q1 revenue forecast with no update to full-year guidance, adding to an 18.6% year-to-date decline. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ENOV

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs